KR20060114091A - An antimicrobial composition comprising lycopene having antimicrobial activity - Google Patents

Abstract

An antimicrobial composition comprising lycopene is provided to have the growth inhibiting activity against pathogenic bacteria, sterilizing effect and hypha formation inhibiting activity and be safely used to human body due to decreased cytotoxicity. The antimicrobial composition against pathogenic bacteria or fungi comprises lycopene having antimicrobial or antifungal activity as an effective ingredient. The pathogenic bacteria are Staphylococcus aureus or Escherichia coli O-157. The pathogenic fungi are Candida albicans, Trichosporon beigelii, Saccharomyces cerevisiae or Malassezia furfur.

Description

Antimicrobial composition comprising lycopene as an active ingredient {An antimicrobial composition comprising lycopene having antimicrobial activity}

1 is a diagram visualizing the antibiosis of lycopene to Staphylococcus aureus,

Figure 2 is a diagram showing the visualization of the lycopene antibiosis against Candida albicans,

Figure 3 is a diagram showing the bactericidal activity of lycopene to Staphylococcus aureus, ○ is treated with propionic acid, and ● is treated with lycopene,

Figure 4 is a diagram showing the bactericidal activity of lycopene against Candida albicans, ○ indicates that treated with amphotericin B, ● indicates lycopene,

5 is a diagram showing the effect of lycopene on the allotype of Candida albicans,

Figures 6a and 6b is a diagram showing the effect of lycopene on the cell cycle of Candida albicans in histogram (Fig. 6a) and bar graph (Fig. 6b),

Figure 7 shows the effect of lycopene on the cell membrane.

The present invention relates to an antimicrobial composition containing lycopene having an antibacterial or antifungal activity as an active ingredient.

In general, direct or indirect damage caused by pathogenic microorganisms causes many economic, environmental and medical problems. Loss due to corruption during the food distribution process in the food industry, the harmful effects of humans and environmental pollution from the use of excessive chemical pesticides on crops in the agricultural industry, and the appearance of antibiotic resistant strains due to the misuse of antibiotics. It is causing problems. In this reality, natural bioactive substances isolated from plants exhibit antimicrobial properties in a wide range of pathogenic bacteria, fungi, etc., but development of new alternatives is urgent in that they can be used environmentally.

Lycopene is a representative carotenoid substance in tomato and tomato foods (Di Mascio P. et al., Arch. Biochem. Biophys., 274 , p532-538, 1989), breast cancer, prostate cancer, lung cancer, etc. Has been reported to inhibit disease (Giovannucci E. et al., J. Natl. Canc. Inst., 91 , p317-331, 1999). It has also been reported that ingestion of lycopene reduces the risk of myocardial infarction (Kohlmeier L. et al., Am. J. Epodemiol., 146 , p618-626, 1997).

However, there is no teaching or disclosure about the antimicrobial or antifungal activity of lycopene anywhere in the literature, and thus the present inventors have completed the present invention by confirming the antimicrobial and antifungal activity of lycopene against pathogenic bacteria and fungi infecting the human body.

An object of the present invention relates to an antimicrobial composition containing lycopene having an antibacterial or antifungal activity as an active ingredient.

In order to achieve the above object, the present invention is to provide an antimicrobial composition against pathogenic bacteria or fungi containing lycopene having an antimicrobial or antifungal activity as an active ingredient.

The pathogenic bacteria include Staphylococcus aureus , Escherichia coli O-157 , etc., and the pathogenic fungi are Candida albicans , Tricospor Beigelai. ( Trichosporon beigelii ), Saccharomyces cerevisiae , Malassezia furfur , and the like.

In another aspect, the present invention contains a lycopene having the antibacterial or antifungal activity as an active ingredient to provide an additive or cosmetic additive composition for food preservation.

Hereinafter, the present invention will be described in detail.

The present invention is to provide an antimicrobial composition against pathogenic bacteria or fungi by containing lycopene having an antibacterial or antifungal activity as an active ingredient.

Lycopene having a structure of formula (1) of the present invention can be separated from a tomato or a food made of tomato, synthesized by a conventional method in the art, or can be purchased and used in a general city.

Lycopene of Formula 1 is a pathogenic bacterium such as Staphylococcus aureus , Escherichia coli O-157 or Candida albicans , Trichosporon beigelii ), Saccharomyces cerevisiae , Malassezia furfur , etc., have growth inhibitory activity against pathogenic fungi, inhibit mycelial formation, and affect cell membranes It exhibits bactericidal activity by inducing loss and by inhibiting cell division by stopping the cell cycle at S phase. In addition, lycopene of the present invention can be prepared for a variety of antimicrobial composition using less cytotoxicity to harm to the human body.

In another aspect, the present invention contains a lycopene having the antibacterial or antifungal activity as an active ingredient to provide an additive or cosmetic additive composition for food preservation.

The present invention can contain the lycopene having an antimicrobial or antifungal activity as an active ingredient to preserve food for a long time by using as an additive for food preservation, and also contains a lycopene having the antibacterial or antifungal activity as an active ingredient as a cosmetic additive It can be used to prepare a cosmetic composition for keeping hands or feet clean.

Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples. However, the following Examples and Experimental Examples are only examples of the present invention, and the present invention is not limited thereto.

Example 1 Preparation of Lycopene and Experimental Strains

To demonstrate the antimicrobial or antifungal activity of lycopene (ψ, ψ-carotene), it was purchased from Sigma Aldrich Korea and stored at -20 ° C until used in the following experiment, dissolved in sterile DMSO (dimethyl sulfoxide) Used for. Staphylococcus aureus , Escherichia coli O-157 , Trichosporon beigelii , Saccharomyces cerevisiae , Marasegia Perl ( Malassezia furfur ) was purchased from the Korea Institute of Bioscience and Technology (KCTC) and Candida albicans from Academic Societies in Osaka, Japan.

Experimental Example 1. Growth inhibitory activity of lycopene against pathogenic microorganisms

In order to determine the antimicrobial activity of lycopene, pathogenic bacteria Staphylococcus aureus , Escherichia coli 0-157 were added to LB complete medium (Tryptone 1%, NaCl 1 %, Yeast extract 0.5%), and diluted to 1 × 10 ⁶ cells / 1 mL of the number of cells, the aliquots of 100 μL in a 96-well plate, the solution of lycopene in 20, 10, 5, 2.5 , 1.25, 0.625 μg. After treatment with the lycopene, while shaking culture for 6 hours in a 37 ℃ incubator using an ELISA reader (reader) by measuring the absorbance at a wavelength of 620 nm to determine the minimum growth inhibition concentration (MIC).

In addition, to measure the antifungal activity of lycopene, pathogenic fungi Candida albicans , Trichosporon beigel-ii , Saccharomyces cerevisiae , Marasegia Perl ( Malassezia furfur ) was incubated in YPD complete medium (2% glucose, 1% peptone, 0.5% yeast extract, pH 5,5), diluted with 2 × 10 ³ cells / 1 mL of bacteria in YPD liquid medium. Dispense 100 μl into a 96-well plate, and then lycopene solution. The amounts were 20, 10, 5, 2.5, 1.25, 0.625 μg. After treatment with the lycopene, shaking culture for 24 hours in an incubator at 28 ℃, MTT [3- (4,5-dimethyl-2-thiazolyl) -2,5-dip-henyl-2H-tetrazolium bromide] solution [ 5 mg of MTT / mL of PBS (pH 7.4)] were added to each well and incubated for 4 hours in a 37 ° C. incubator. To dissolve Formazan produced by MTT, 20 μl of 20% SDS containing 0.02 N HCl was added and reacted at 37 ° C. for 16 hours. The minimum growth inhibition concentration (MIC) was determined by measuring the absorbance of each well under a wavelength of 570 nm with an ELISA reader. As a control of the experiment, the experiment was performed by treating propionic acid, which is used as an additive for food preservation, and amphotericin B, an antifungal agent.

As a result of the experiment, as shown in Table 1, the antimicrobial activity of lycopene has antimicrobial activity in a wide range of pathogenic bacteria including Gram positive and negative bacteria, and the minimum growth inhibition concentration (MIC) is mostly 5-10 ㎍. As a result, it was confirmed that the food industry exhibited superior antimicrobial activity than propionic acid used as an additive (preservative) for food preservation. As a result of measuring the antifungal activity of lycopene, it showed a minimum growth inhibitory concentration of 2.5-5 ㎍ against pathogenic fungi, which was similar to that of amphotericin B, a potent antifungal agent used in the control clinic. It was found to exhibit potent antifungal activity. Table 1 a shows the concentration of lycopene in which no pathogenic microorganisms are grown, and b means that the MIC concentration is not determined.

Minimum growth inhibitory concentration (MIC) of lycopene for pathogenic microorganisms MIC ^a (μg / mL) for pathogenic microorganisms Pathogenic bacteria Pathogenic fungi S. Aureus Escherichia coli O-157 C. Albicans T. Begelai S. Serbia M. Pearl Lycopene 5 10 5 5 5 2.5 Propionic acid 10 20 ND ^b ND ND ND Amphotericin B ND ND 2.5-5 5 2.5 0.3125

Experimental Example 2 Visual Observation of Antimicrobial Activity of Lycopene

To visualize the antimicrobial activity, Staphylococcus aureus was incubated in LB liquid medium, and then diluted with LB medium so that the cell number was 1 × 10 ⁶ cells / 1 mL. After that, 10 μg of lycopene solution was treated and incubated for 6 hours in a 37 ° C. incubator. After the incubation, the plate was plated in an LB solid medium Petri dish and cultured in a 37 ° C. incubator to take a Petri dish photo.

In addition, in order to visualize antifungal activity, Candida albicans was cultured in YPD liquid medium, and then diluted with YPD medium so that the number of cells was 2 × 10 ³ cells / 1 mL. Thereafter, 5 μg of lycopene solution was treated and incubated for 18 hours in a 28 ° C. incubator. After incubation, the plate was plated on a YPD solid medium Petri dish and cultured in a 28 ° C. incubator to take a Petri dish. As a control of the experiment, the experiment was performed by treating 20 µg of propionic acid, which is used as an additive for preserving food, and 2.5 µg of amphotericin B, an antifungal agent.

As a result of the above experiment, as shown in Fig. 1 and Fig. 2, 20 μg of priponic acid treatment in the group treated with 10 μg of the lycopene of the present invention (b in Fig. 1) as compared to the untreated group (A in Fig. 1). It was confirmed that the antimicrobial activity was almost similar to the group (Fig. 1 C) (see Fig. 1), and also the antifungal activity (see Fig. 2) also 5 ㎍ of lycopene of the present invention compared to the untreated group (A of Fig. 2) In the treatment group (b of FIG. 2), it was confirmed that the antifungal activity was almost similar to that of the 2.5 μg amphotericin B treatment group (c in FIG. 2).

Experimental Example 3. Antibiotics test of lycopene over time

The time-dependent measurement of antimicrobial activity was determined by culturing Staphylococcus aureus in LB medium, diluting the cells in 96-well plates by diluting the cell number to 1 × 10 ⁶ cells / 1 mL. . Thereafter, 10 µg of a solution of lycopene was treated and incubated at 37 ° C., and then plated in a LB solid medium Petri dish at a predetermined time to determine the number of colonies formed by culturing the petri dish smeared at 37 ° C.

The time-dependent measurement of antifungal activity was incubated in Candida albicans in YPD medium, and then diluted in a 96-well plate by diluting the cell number to 2 × 10 3 cells / 1 mL. Thereafter, 5 μg of a solution of lycopene was treated and incubated at 28 ° C., and then plated in a YPD solid medium Petri dish at predetermined times to determine the number of colonies formed by culturing the petri dish plated in a 28 ° C. incubator. As a control of the experiment, the experiment was performed by treating 20 µg of propionic acid, which is used as an additive for preserving food, and 2.5 µg of amphotericin B, an antifungal agent.

As a result of the above experiment, when the lycopene of the present invention was treated as shown in Figure 3 and 4, the survival of pathogenic bacteria could not be confirmed after about 150 minutes (see Figure 3), and also about the pathogenic fungi After 9 hours, its survival could not be confirmed, which showed almost the same effect as pripionic acid and amphotericin B, respectively.

Experimental Example 4. Effect of lycopene on homomorphic heteromorphism

The following experiment was performed to determine the effect of lycopene of the present invention on essential dimorphic transitions that cause pathogenicity when Candida albicans is infected in the body. Candida albicans was incubated in YPD medium, then diluted with YPD medium so that the cell number was 2 × 10 ³ cells / 1 mL and the dilutions were dispensed into 96-well plates. Subsequently, 10% and 20µg of lycopene solutions were treated respectively, and 20% calf serum (Fetal bovine serum) was added to the group treated with 10µg of lycopene to adjust the in vivo conditions. The morphological changes of the bacteria were observed while culturing in the incubator.

As a result of performing the experiment, as shown in FIG. 5, when only the serum solution of the calf as a control group was added to form a mycelium (see FIG. 5), the lycopene 10μg and calf serum treatment group of the present invention (FIG. 5) ) And lycopene 20 μg treated group (see C in Figure 5) was confirmed that mycelia formation is inhibited. It has been found that lycopene can prevent the onset of Candida albicans in vivo.

Experimental Example 5. Effect of Lycopene on Cell Cycle

After cultivating Candida albicans in YPD medium, dilute with YPD medium so that the cell number becomes 2 × 10 ⁵ cells / 1 mL and dispense into eppen rope tube, add 50 μg of lycopene solution and incubate at 28 ° C. Incubated for hours. After incubation, 1 ml of 100% ethanol solution was added to fix the cells and incubated at 4 ° C for 24 hours. The fixed cells were washed twice with 1 ml of pH 7.4 phosphate-sodium chloride buffer (PBS), added with RNA degrading enzyme (RNAse, 100 μg / ml) with 0.5 ml sodium phosphate-chloride buffer and incubator at 37 ° C. for 1 hour. Reacted. Then, Propidium iodide (50 µg / ml), a material for staining DNA with 0.5 ml phosphate-sodium chloride buffer, was added and stained at 4 ° C. for 1 hour, followed by propidium iodide staining. According to the cell cycle was analyzed.

As a result of the experiment, it was confirmed that the cell cycle is stopped at the G2 / M stage by lycopene, as shown in FIGS. 6a and 6b, whereby the antibiotic activity of lycopene inhibits the cell cycle of pathogenic microorganisms. (A in FIG. 6a and 6b in FIG. 6a is an untreated group, and □ in FIG. 6a and b in FIG. 6b is a 50 µg lycopene treatment group).

Experimental Example 6. Effect of Lycopene on Cell Membrane

After cultivating Candida albicans in YPD medium, dilute with YPD medium so that the cell number becomes 2 × 10 ⁵ cells / 1 mL and dispense into eppen rope tubes, add 80 μg of lycopene solution and incubate at 28 ° C. Incubated for hours. After washing twice with 1 ml of pH 7.4 phosphate-sodium chloride buffer (PBS) and with 1 ml phosphate-sodium chloride buffer, when the cell membrane loses function and is depolarized, it is a substance that accumulates inside the cell through the cell membrane. bis- (1,3-Dibutylbarbituric acid)-Trimeyhine Oxonol (BOX, 50µg / ml) was added and stained at 4 ° C for 1 hour. The change in cell membrane was measured according to the degree of staining of the BOX.

As a result of the experiment, as shown in Figure 7, it was confirmed that the biofilm function of the cell membrane was lost by lycopene, whereby it can be confirmed that the antibiotic activity of lycopene shows the antibiotic activity by damaging the cell membrane of pathogenic microorganisms. there was.

Experimental Example 7. Cytotoxicity Test

Cytotoxicity of lycopene to human red blood cells was measured by the following method. Erythrocytes (Human erythrocytes) were washed three times with pH 7.4 phosphate-sodium chloride buffer (PBS) and then diluted with phosphate-sodium chloride buffer to prepare 8.0% erythrocyte cell solutions. Thereafter, 100 μl of the 8.0% erythrocyte cell solution was dispensed into 96-well plates, and then the solution of lycopene was mixed in amounts of 10, 5, 2.5, 1.25, and 0.625 μg. The saline solution (Saline 0.85% NaCl) was added to all the wells so that the total amount was 200 μl, and the cells were incubated for 1 hour in a 37 ° C. incubator. After incubation, the supernatant was transferred to the side wells by centrifugation for 10 minutes at a rotational speed of 1000 rpm in a centrifuge. Destructive capacity for erythrocytes was analyzed by measuring the absorbance under a wavelength of 414 nm with an ELISA reader. And when treated with 0.1% Triton X-100 as a control, the value was calculated as 100% destructive capacity, and only the red blood cells were counted as 0% destructive capacity. The breaking ability of lycopene was calculated by the following equation.

% Fracture Capacity = [(absorbance of lycopene treated solution _414nm -absorbance of PBS _414nm ) / (absorbance of triton X-100 treated solution _414nm -PBS absorbance _414nm ) × 100

As a result of the experiment, as shown in Table 2, the lycopene of the present invention was confirmed to exhibit weak cytotoxicity at high concentrations. In comparison, amphotericin B, which is used as an antifungal agent in the clinic, showed high cytotoxicity even at low concentrations, and propionic acid used in the food industry did not exhibit cytotoxicity. Therefore, it was determined that lycopene found in the present invention can be used in humans without damaging the human body within the range of not using excessive amounts.

Cytotoxicity of Lycopene on Human Erythrocytes % Human erythrocyte destructive capacity ^a (µg / ml) 10 50 2.5 1.25 0.625 Lycopene 12.2 0 0 0 0 Pripionic acid 0 0 0 0 0 Amphotericin B 76.6 20.8 5.8 4.6 3.7

As described above, the present invention relates to an antimicrobial composition containing lycopene having an antibacterial or antifungal activity as an active ingredient, wherein the lycopene of the present invention is Staphylococcus aureus , E. coli O Pathogenic bacteria, such as Escherichia coli O-157 , or Candida albicans , Trichosporon beigelii , Saccharomyces cerevisiae , Marasegia pearl pearl Malassezia furfur ) has growth inhibitory activity against pathogenic fungi, bactericidal activity, inhibition of mycelial formation, loss of biological function of cell membranes of pathogenic fungi, and remarkably reduced cytotoxicity. Useful as an antibiotic, food preservative additive or cosmetic additive composition containing the lycopene of the present invention It is applicable.

Claims (4)

A composition for antibacterial against pathogenic bacteria or fungi by containing lycopene having an antibacterial or antifungal activity as an active ingredient. The method of claim 1, wherein the pathogenic bacteria are Staphylococcus aureus or Escherichia coli O-157 , the pathogenic fungi Candida albicans Candida albicans , Tricospor Bay Antibacterial composition characterized in that the gel ( Trichosporon beigelii ), Saccharomyces cerevisiae ( Saccharomyces cerevisiae ) or Malassezia furfur ( Malassezia furfur ). An additive composition for food preservation having antimicrobial or antifungal activity by containing lycopene of claim 1 as an active ingredient. Cosmetic additive composition having antimicrobial or antifungal activity by containing the lycopene of claim 1 as an active ingredient.

Images